{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/1604467445",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/428256012"
  ],
  "child": [
    "http://id.who.int/icd/release/11/2024-01/mms/2086270207",
    "http://id.who.int/icd/release/11/2024-01/mms/464753737"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#1604467445",
  "code": "",
  "source": "http://id.who.int/icd/entity/1604467445",
  "classKind": "block",
  "foundationChildElsewhere": [
    {
      "label": {
        "@language": "en",
        "@value": "Predominantly alpha-adrenoreceptor and dopamine receptor agonists"
      },
      "foundationReference": "http://id.who.int/icd/entity/1670206891",
      "linearizationReference": "http://id.who.int/icd/release/11/2024-01/mms/1670206891"
    },
    {
      "label": {
        "@language": "en",
        "@value": "Predominantly beta-adrenoreceptor agonists"
      },
      "foundationReference": "http://id.who.int/icd/entity/1184107373",
      "linearizationReference": "http://id.who.int/icd/release/11/2024-01/mms/1184107373"
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Adrenergic agonists"
  }
}